434P First-line oxaliplatin-based chemoimmunotherapy for advanced HER2/neu-negative gastric and gastroesophageal junction cancer: A systematic review and network meta-analysis.

MLA

Al Zahrani, A., et al. “434P First-Line Oxaliplatin-Based Chemoimmunotherapy for Advanced HER2/Neu-Negative Gastric and Gastroesophageal Junction Cancer: A Systematic Review and Network Meta-Analysis.” Annals of Oncology, vol. 35, June 2024, p. S175. EBSCOhost, https://doi.org/10.1016/j.annonc.2024.05.346.

APA

Al Zahrani, A., Alsuwailem, R., Alghamdi, F., Alfahadi, A., Elhassan, T., & Yezli, S. (2024). 434P First-line oxaliplatin-based chemoimmunotherapy for advanced HER2/neu-negative gastric and gastroesophageal junction cancer: A systematic review and network meta-analysis. Annals of Oncology, 35, S175. https://doi.org/10.1016/j.annonc.2024.05.346

Chicago

Al Zahrani, A., R. Alsuwailem, F. Alghamdi, A. Alfahadi, T. Elhassan, and S. Yezli. 2024. “434P First-Line Oxaliplatin-Based Chemoimmunotherapy for Advanced HER2/Neu-Negative Gastric and Gastroesophageal Junction Cancer: A Systematic Review and Network Meta-Analysis.” Annals of Oncology 35 (June): S175. doi:10.1016/j.annonc.2024.05.346.